Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine

Martina Zátopková, Tereza Ševčíková, Viola Fanfani, Zuzana Chyra, Lucie Rihova, Renata Bezdekova, David Žihala, Kateřina Growková, Jana Filipova, Lucie Černá, Lucie Broskevičová, Fedor Kryukov, Jiří Minařík, Jana Smejkalová, Vladimir Maisnar, Lubica Harvanová, Ludek Pour, Alexandra Jungova, Tereza Popková, Juli Rodriguez BagoAnjana Anilkumar Sithara, Matous Hrdinka, Tomas Jelinek, Michal Šimíček, Giovanni Stracquadanio, Roman Hajek

Research output: Contribution to journalArticlepeer-review

Abstract

Multiple myeloma (MM) measurable residual disease (MRD) persisting after treatment is an adverse prognostic factor for progression free survival (PFS) and overall survival.1Genomic mutations occurred in the remaining clonal aberrant plasma cells (A-PCs) are linked to the development of drug resistance and disease relapse.2 Thus, personalised treatment based on the genomic profile of MRD could be highly beneficial and ultimately increase patients’ survival. However, while large-scale sequencing studies have characterised the genome of many malignancies including MM,3–8 the genomic mutations present in MM MRD are at the beginning of investigation.9 Here, we set up an exome sequencing analysis to identify genomic mutations characteristic for MM MRD and explore if they could mediate drug response, resistance or disease progression.
Original languageEnglish
Number of pages9
JournalBlood Advances
Early online date9 Sep 2021
DOIs
Publication statusE-pub ahead of print - 9 Sep 2021

Keywords

  • multiple myeloma
  • mutation
  • precision medicine
  • residual tumor

Fingerprint

Dive into the research topics of 'Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine'. Together they form a unique fingerprint.

Cite this